Join the Life Science Technology User Group for our “AI’nt this off the Chain?: AI and Block Chain in Life Sciences” event on September 11th from 5:00PM - 8:00 PM. We'll have a thought-provoking, informative and interactive session followed by a reception.
5:00 PM - 5:15 PM Check-in, Networking, Refreshments
5:15 PM - 5:45 PM “The Promise and the Myth of AI in Transforming Biopharma” with John Veytsman, Sr. Business Analyst, Biogen
5:45 PM - 6:00 PM Break
6:00 PM - 6:45 PM “AI and Blockchain in Biotech: Promise, Hype, and Challenges” with Poorya Hosseini, Associate, Flagship Pioneering
6:45 PM - 8:00 PM Reception
More about our speakers:
Poorya Hosseini, Ph.D., Associate, Flagship Pioneering
Poorya is an associate at Flagship Pioneering, working as part of a team of entrepreneurial scientists to conceive, create, resource and develop the next generation of Flagship’s first-in-category ventures. He is a founding member of VL49 Inc. (stealth mode) that aims to leverage cutting-edge computational tools in combination with biological omics to develop pioneering therapeutic solutions for cancer, immune, and inflammatory diseases.
Prior to joining the firm, Poorya completed his doctoral studies at the Massachusetts Institute of Technology (MIT). Poorya’s thesis work at MIT focused on the development of advanced label-free imaging techniques for studying biophysical properties of cells and tissues. Poorya has received several awards for his academic work, including the Edison Award for Impactful Research at MIT and the Iranian-American Medical Association’s Young Investigator Award for his work on anemic disorders. In addition to his scientific and entrepreneurial focus, Poorya is deeply interested in political science broadly, international relations, playing all sort of sports and fishing!
John Veytsman, Sr. Business Analyst, Biogen
John Veytsman is a Sr. Business Analyst within Biogen's R&D Information Technology group. He has a breadth of experience working across different functional domains ranging from Commercial to R&D and now in clinical devices / digital biomarkers. He has been a key advocate for artificial intelligence approaches to solving strategic problems across Biogen. He has played an instrumental role in the conceptualization and implementation of AI based solutions, ranging from target ID and validation initiatives in early discovery research to collaboration initiatives company-wide.
Register here: https://dell.captix.com/event/BBavYd/register